GNLX Insider Transactions
146 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 1–100; provenance stays internal.
GNLX insiders transaction timeline
PurchaseSale
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| Yu Yong | Chief Scientific Officer | 2026-08-04 | Sale | 653 | $2.9434 |
| Cappello Joseph | Chief Technical Officer | 2026-08-04 | Sale | 653 | $2.9467 |
| Zindrick Thomas | President and CEO | 2026-08-04 | Sale | 3,023 | $2.9459 |
| Smither John W | Director | 2026-07-01 | Sale | 12,000 | $2.9082 |
| Smalling Ralph | Head of Regulatory | 2026-06-03 | Sale | 192.0 | $2.93 |
| Thomas John | Director | 2026-06-01 | Sale | 10,000.0 | $2.98 |
| Cappello Joseph | Chief Technical Officer | 2026-05-11 | Sale | 605.0 | $2.97 |
| Yu Yong | Chief Scientific Officer | 2026-05-11 | Sale | 605.0 | $2.97 |
| Zindrick Thomas | President and CEO | 2026-05-11 | Sale | 2,798.0 | $2.94 |
| Smalling Ralph | Head of Regulatory | 2026-05-11 | Sale | 270.0 | $2.98 |
| Smalling Ralph | Head of Regulatory | 2026-03-25 | Sale | 240.0 | $2.51 |
| Smalling Ralph | Head of Regulatory | 2026-03-24 | Sale | 345.0 | $2.42 |
| Cappello Joseph | Chief Technical Officer | 2026-03-24 | Sale | 906.0 | $2.42 |
| Yu Yong | SVP, Clinical Development | 2026-03-24 | Sale | 906.0 | $2.42 |
| Zindrick Thomas | President and CEO | 2026-03-24 | Sale | 3,582.0 | $2.42 |
| Thomas John | Director | 2026-03-02 | Sale | 10,000.0 | $2.9 |
| Smalling Ralph | Head of Regulatory | 2025-12-05 | Sale | 165.0 | $4.69 |
| Thomas John | Director | 2025-12-01 | Sale | 10,000.0 | $5.0 |
| Zindrick Thomas | President and CEO | 2025-11-17 | Sale | 4,509.0 | $5.37 |
| Yu Yong | SVP, Clinical Development | 2025-11-17 | Sale | 973.0 | $5.37 |
| Cappello Joseph | Chief Technical Officer | 2025-11-17 | Sale | 973.0 | $5.37 |
| Smalling Ralph | Head of Regulatory | 2025-11-17 | Sale | 343.0 | $5.37 |
| Smalling Ralph | Head of Regulatory | 2025-09-03 | Sale | 580.0 | $3.36 |
| Zindrick Thomas | President and CEO | 2025-08-21 | Sale | 12,673.0 | $3.33 |
| Yu Yong | SVP, Clinical Development | 2025-08-21 | Sale | 3,219.0 | $3.36 |
| Cappello Joseph | Chief Technical Officer | 2025-08-21 | Sale | 1,463.0 | $3.36 |
| Cappello Joseph | Chief Technical Officer | 2025-08-21 | Sale | 1,270.0 | $3.33 |
| Smalling Ralph | Head of Regulatory | 2025-08-21 | Sale | 1,244.0 | $3.36 |
| Ryder Sean | General Counsel | 2025-05-12 | Sale | 4,475.0 | $2.92 |
| Zindrick Thomas | President and CEO | 2025-05-12 | Sale | 10,764.0 | $2.92 |
| Yu Yong | VP, Clinical Trial Operations | 2025-05-12 | Sale | 5,579.0 | $2.92 |
| Cappello Joseph | VP, Pharmaceutical Development | 2025-05-12 | Sale | 4,737.0 | $2.92 |
| Smalling Ralph | Head of Regulatory | 2025-05-12 | Sale | 1,259.0 | $2.92 |
| Tyree James L | Director | 2024-12-30 | Sale | 3,460.0 | $2.46 |
| Zindrick Thomas | President and CEO | 2024-12-16 | Sale | 14,315.0 | $2.34 |
| Zak Lourie S. | Chief Financial Officer | 2024-12-16 | Sale | 2,103.0 | $2.34 |
| Smalling Ralph | Head of Regulatory | 2024-12-16 | Sale | 2,510.0 | $2.34 |
| Cappello Joseph | VP, Pharmaceutical Development | 2024-12-16 | Sale | 6,300.0 | $2.34 |
| Szalay Aladar | TenPercentOwner | 2024-09-13 | Sale | 33,080.0 | $2.57 |
| Szalay Aladar | TenPercentOwner | 2024-09-12 | Sale | 31,777.0 | $2.73 |
| Tyree James L | Director | 2024-09-11 | Sale | 1,730.0 | $2.6 |
| Szalay Aladar | TenPercentOwner | 2024-09-11 | Sale | 31,376.0 | $2.62 |
| Szalay Aladar | TenPercentOwner | 2024-09-10 | Sale | 20,384.0 | $2.51 |
| Szalay Aladar | TenPercentOwner | 2024-09-09 | Sale | 23,383.0 | $2.7 |
| Szalay Aladar | TenPercentOwner | 2024-09-03 | Sale | 42,818.0 | $2.09 |
| Szalay Aladar | TenPercentOwner | 2024-08-30 | Sale | 142,589.0 | $2.17 |
| Szalay Aladar | TenPercentOwner | 2024-08-29 | Sale | 107,045.0 | $1.98 |
| Szalay Aladar | TenPercentOwner | 2024-08-28 | Sale | 15,918.0 | $2.05 |
| Szalay Aladar | TenPercentOwner | 2024-08-27 | Sale | 51,630.0 | $2.11 |
| Szalay Aladar | TenPercentOwner | 2024-08-23 | Sale | 40,000.0 | $2.29 |
| Yu Yong | VP, Clinical Trial Operations | 2024-06-24 | Sale | 6,849.0 | $2.12 |
| Ryder Sean | General Counsel | 2024-06-24 | Sale | 5,496.0 | $2.12 |
| Jewett Caroline | Head of Quality | 2024-06-24 | Sale | 4,961.0 | $2.12 |
| Tyree James L | Director | 2024-05-29 | Purchase | 6,250.0 | — |
| Smither John W | Director | 2024-05-29 | Purchase | 6,250.0 | — |
| Thomas John | Director | 2024-05-29 | Purchase | 2,500.0 | — |
| Mirabelli Mary | Director | 2024-05-29 | Purchase | 8,000.0 | — |
| Yu Yong | VP, Clinical Trial Operations | 2024-05-29 | Purchase | 2,500.0 | — |
| Zindrick Thomas | President and CEO | 2024-05-29 | Purchase | 200,000.0 | — |
| Smalling Ralph | Head of Regulatory | 2024-05-29 | Purchase | 1,250.0 | — |
| Ryder Sean | General Counsel | 2024-05-29 | Purchase | 10,000.0 | — |
| Zak Lourie S. | Chief Financial Officer | 2024-05-29 | Purchase | 31,250.0 | — |
| Szalay Aladar | TenPercentOwner | 2024-05-15 | Sale | 17,094.0 | $3.66 |
| Szalay Aladar | TenPercentOwner | 2024-05-14 | Sale | 15,426.0 | $3.58 |
| Szalay Aladar | TenPercentOwner | 2024-05-13 | Sale | 3,446.0 | $3.62 |
| Szalay Aladar | TenPercentOwner | 2024-05-08 | Sale | 13,919.0 | $3.82 |
| Szalay Aladar | TenPercentOwner | 2024-05-07 | Sale | 6,025.0 | $3.67 |
| Szalay Aladar | TenPercentOwner | 2024-05-01 | Sale | 33,061.0 | $3.3 |
| Szalay Aladar | TenPercentOwner | 2024-04-30 | Sale | 20,535.0 | $3.12 |
| Szalay Aladar | TenPercentOwner | 2024-04-29 | Sale | 6,403.0 | $3.25 |
| Szalay Aladar | TenPercentOwner | 2024-04-24 | Sale | 8,064.0 | $3.5 |
| Szalay Aladar | TenPercentOwner | 2024-04-23 | Sale | 22,000.0 | $3.49 |
| Szalay Aladar | TenPercentOwner | 2024-04-22 | Sale | 14,331.0 | $3.53 |
| Szalay Aladar | TenPercentOwner | 2024-04-17 | Sale | 22,737.0 | $3.71 |
| Szalay Aladar | TenPercentOwner | 2024-04-16 | Sale | 48,683.0 | $3.53 |
| Yu Yong | VP, Clinical Trial Operations | 2023-12-15 | Sale | 5,803.0 | $14.18 |
| Yu Yong | VP, Clinical Trial Operations | 2023-12-15 | Sale | 26,732.0 | $12.94 |
| Tyree James L | Director | 2023-12-13 | Sale | 3,347.0 | $13.73 |
| Tyree James L | Director | 2023-12-13 | Sale | 5,653.0 | $12.91 |
| Thomas John | Director | 2023-12-13 | Sale | 1,927.0 | $13.93 |
| Thomas John | Director | 2023-12-13 | Sale | 7,073.0 | $13.23 |
| Yu Yong | VP, Clinical Trial Operations | 2023-12-07 | Sale | 36,800.0 | $11.85 |
| Yu Yong | VP, Clinical Trial Operations | 2023-11-21 | Sale | 18,665.0 | $10.26 |
| Yu Yong | VP, Clinical Trial Operations | 2023-11-20 | Sale | 14,594.0 | $11.26 |
| Yu Yong | VP, Clinical Trial Operations | 2023-11-17 | Sale | 3,541.0 | $13.04 |
| Szalay Aladar | TenPercentOwner | 2023-10-25 | Sale | 5,704.0 | $19.4 |
| Yu Yong | VP, Clinical Trial Operations | 2023-10-24 | Sale | 5,200.0 | $19.11 |
| Szalay Aladar | TenPercentOwner | 2023-10-23 | Sale | 49,987.0 | $19.97 |
| Thomas John | Director | 2023-10-16 | Sale | 881.0 | $21.3 |
| Thomas John | Director | 2023-10-16 | Sale | 2,452.0 | $20.5 |
| Yu Yong | VP, Clinical Trial Operations | 2023-10-10 | Sale | 400.0 | $22.91 |
| Yu Yong | VP, Clinical Trial Operations | 2023-10-10 | Sale | 4,800.0 | $21.94 |
| Szalay Aladar | TenPercentOwner | 2023-10-05 | Sale | 985.0 | $25.47 |
| Szalay Aladar | TenPercentOwner | 2023-10-05 | Sale | 13,266.0 | $24.89 |
| Szalay Aladar | TenPercentOwner | 2023-10-03 | Sale | 75,690.0 | $25.49 |
| Szalay Aladar | TenPercentOwner | 2023-09-28 | Sale | 2,289.0 | $24.12 |
| Szalay Aladar | TenPercentOwner | 2023-09-27 | Sale | 11,257.0 | $24.47 |
| Szalay Aladar | TenPercentOwner | 2023-09-26 | Sale | 9,600.0 | $24.51 |
| Szalay Aladar | TenPercentOwner | 2023-09-26 | Sale | 12,740.0 | $24.03 |
| Szalay Aladar | TenPercentOwner | 2023-09-26 | Sale | 7,465.0 | $22.47 |